Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dong-A to set up biosimilar production plant in Songdo
The facility is intended to target the global markets with antibody based drugs including Herceptin biosimilar. Dong-A and Japanese company, Meiji Seika Pharma signed an agreement to develop
The facility is intended to target the global markets with antibody based drugs including Herceptin biosimilar. Dong-A and Japanese company, Meiji Seika Pharma signed an agreement to develop
ICT-107 is a dendritic cell-based vaccine which targets multiple tumor associated antigens for glioblastoma, for its Phase II clinical trial. Under the agreement, PCT will transfer and qualify
Syngas is the key precursor for the production of oxo intermediates and oxo derivatives, which are used in pharmaceutical products. The manufacturing facility develops oxo chemicals, synthetic fatty
The US Department of Health and Human Services for the Influenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD) has offered to fund the research.
The delivery system will be based upon TriLogic drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development with focus on women’s health
Silenor is used for the treatment of insomnia characterized by difficulty with sleep maintenance. According to the company, FDA provided clinical and regulatory guidance is believed to help
The CFCs present in the product deplete the earth’s ozone layer. The decision follows the Montreal Protocol treaty to stop the use of substances that damage the environment.
BioThrax vaccine is licensed by the US Food and Drug Administration (FDA) to protect against anthrax infection. Under this award, the initial deliveries are likely to begin in
Benefix RTS can be stored for up to two years at room temperature (2-30°C) for about two years, thereby providing more convenience to haemophilia B patients, europeanpharmaceuticalreview reported.
The settlement includes a license by MDCO to Teva and its affiliates under which Teva may launch a generic bivalirudin product. Teva admits that the two patents asserted